Phase I safety, efficacy, and biomarker response evaluations of three oral PD-L1 inhibitors: INCB086550, INCB099280, and INCB099318
Hans Prenen, Sylvie Rottey, David J. Pinato, Thierry Lesimple et autres
0 citationsJournal for ImmunoTherapy of Cancer